Ashling Wahner

Abequolixron plus docetaxel generated preliminary efficacy signals in the second- and third-line settings in recurrent advanced nonsquamous NSCLC.

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.

Treatment with afami-cel was associated with long-term persistence in the periphery that led to clinical benefit in patients with synovial sarcoma.

Whitney Goldsberry, MD, discusses patient characteristics and disease factors that sway the decision between available PARP inhibitors in ovarian cancer.

Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.

Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.

The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.

The FDA approved the FoundationOne Liquid CDx to identify patients with mNSCLC with MET exon 14 skipping alterations who may be eligible for tepotinib.

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.

Mark Awad, MD, PhD, and Jonathan Spicer, MD, PhD, discuss the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.

Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Treatment with magrolimab plus docetaxel led to peripheral CD47 saturation in patients with advanced NSCLC, which correlated with improved outcomes.

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.

Lasofoxifene was well tolerated and had early activity signals in patients with HR-positive, HER2-negative, locally advanced breast cancer.

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.

Jairam Krishnamurthy, MD, FACP, discusses the selective use of CDK4/6 inhibitors after prior progression on these agents in patients with breast cancer.

Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.

Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.